首页> 外文期刊>Parasite Immunology >Favourable prognostic value of antibodies anti-HSP20 in patients with cystic echinococcosis: a differential immunoproteomic approach.
【24h】

Favourable prognostic value of antibodies anti-HSP20 in patients with cystic echinococcosis: a differential immunoproteomic approach.

机译:抗HSP20抗体在囊性棘球co虫病患者中具有良好的预后价值:一种不同的免疫蛋白质组学方法。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Seeking biomarkers reflecting disease development in cystic echinococcosis (CE), we used a proteomic approach linked to immunological characterisation for the identification of respective antigens. Two-dimensional gel electrophoresis (2-DE) of sheep hydatid fluid, followed by immunoblot analysis (IB) with sera from patients with distinct phases of disease, enabled us to identify by mass spectrometry heat shock protein 20 (HSP20) as a potential marker of active CE. Using IB, antibodies specific to the 34 kDa band of HSP20 were detected in sera from 61/95 (64%) patients with CE, but not in sera from healthy subjects. IB revealed anti-HSP20 antibodies in a higher percentage of sera from patients with active disease than in sera from patients with inactive disease (81 vs. 24%; P=10-4). These primary results were confirmed in a long-term follow-up study after pharmacological and surgical treatment. Herewith anti-HSP20 antibody levels significantly decreased over the course of treatment in sera from patients with cured disease, relative to sera from patients with progressive disease (P=0.017). Thus, during CE, a comprehensive strategy of proteomic identification combined with immunological validation represents a promising approach for the identification of biomarkers useful for the prognostic assessment of treatment of CE patients.
机译:为了寻找反映囊性包虫病(CE)中疾病发展的生物标志物,我们使用了与免疫学特征相关的蛋白质组学方法来鉴定各个抗原。羊hy虫液的二维凝胶电泳(2-DE),然后用疾病不同阶段患者的血清进行免疫印迹分析(IB),使我们能够通过质谱鉴定热休克蛋白20(HSP20)作为潜在标记物主动CE。使用IB,在61/95(64%)CE患者的血清中检测到对HSP20的34 kDa带具有特异性的抗体,但在健康受试者的血清中未检测到。 IB显示,患有活动性疾病的患者血清中抗HSP20抗体的比例高于非活动性疾病患者的血清中(81%vs. 24%; P = 10 -4 )。在药物和手术治疗后的长期随访研究中证实了这些主要结果。因此,相对于进行性疾病患者的血清,在治愈疾病患者的血清中抗HSP20抗体水平在治疗过程中显着降低(P = 0.017)。因此,在CE期间,蛋白质组学鉴定与免疫学验证相结合的综合策略代表了一种有前途的方法,可用于鉴定可用于治疗CE患者的预后评估的生物标记物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号